10 C.F.R. § 20.1402
Radiological criteria for unrestricted use
A site will be considered acceptable for unrestricted use if the residual radioactivity that is distinguishable from background radiation results in a TEDE to an average member of the critical group that does not exceed 25 mrem (0.25 mSv) per year, including that from groundwater sources of drinking water, and that the residual radioactivity has been reduced to levels that are as low as reasonably achievable (ALARA). Determination of the levels which are ALARA must take into account consideration of any detriments, such as deaths from transportation accidents, expected to potentially result from decontamination and waste disposal.
Notes of Decisions
Cited in 3
cases (1 in the last 5 years), 2013–2025 · leading case: Shieldalloy Metallurgical Corp. v. Nuclear Regulatory Comm'n, 768 F.3d 1205 (D.C. Cir. 2014).
Shieldalloy Metallurgical Corp. v. Nuclear Regulatory Comm'n, 768 F.3d 1205 (D.C. Cir. 2014). “See 10 C.F.R. § 20.1402 . By way of context, a chest xray typically gives a dose of 10 millirem.”
Shieldalloy Metallurgical Corp. v. Nuclear Regulatory Comm'n, 707 F.3d 371 (D.C. Cir. 2013). “No such demonstration is required for unrestricted release, 10 C.F.R. § 20.1402 . 3 This contrast confirms the NRC’s interpretation of its regulations as not envisioning a dose comparison or that such a comparison dictates the choice of decommissioning method.”
Tpmc-Energysolutions Env't Servs. 2008, LLC v. United States (Fed. Cl. 2025). “See 10 C.F.R. 20.1402. At trial, the parties jointly moved to admit into evidence the “REVISED FINAL DECOMMISSIONING PLAN,” which described the NRC decommissioning process, as the process applied to the LLRBS: The steps in the process (based on current regulations and guidance)…”
Annotations are extracted automatically from the opinions in the
Syfert caselaw corpus and ranked by authority, recency, and
treatment. Dots show Syfertize treatment of the citing case itself.